- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02030912
Effect of Minocycline & Amoxicillin on Antibiotic Resistant Bacteria and Indigenous Microbiotas (ANTIRESDEV)
Phase 4 Study Into the Effect of Minocycline and Amoxicillin Administration of the Prevalence of Antibiotic Resistant Bacteria and on the Indigenous Oral, Faecal, Cutaneous and Nasal Microbiotas
A randomised, open labelled study design is selected in order to determine the emergence and persistence of antibiotic resistant bacteria in humans and on the composition of the indigenous microbiotas at various body sites. These will involve the administration to volunteers of minocycline and amoxicillin- a control group will receive a placebo. Microbiology of the skin, saliva, faecal, skin and nasal micro flora, safety and adverse events, vital signs, will be evaluated. The objectives of metagenomic analysis are:
- To identify the in vivo molecular mechanisms responsible for antibiotic resistance and its transfer in the indigenous oral and faecal microbiotas using metagenomics resistome analysis.
- To determine the impact of the use of antimicrobial agents on the oral resistome
- To determine the impact of the use of antimicrobial agents on the faecal resistome
- To determine the ecological impact of the use of antimicrobial agents on the relative abundance of phylotypes of the indigenous oral microbiota
- To determine the ecological impact of the use of antimicrobial agents on the relative abundance of phylotypes of the indigenous faecal microbiotas
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, SW17 0RE,
- Richmond Pharmacology Ltd
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women aged between 18 and 40 years.
- Following verbal & written information about the trial, the subject has signed & dated informed consent before any study related activity was carried out.
- Subject legally competent and able to communicate effectively with the study personnel
- Normal finding in the medical history and physical examination, unless the investigator considers an abnormality to be clinically irrelevant.
- Male or female subjects who are using a medically acceptable method of contraception or of non-childbearing potential (i.e., surgically sterile-bilateral tubal ligation or removal of both ovaries and/or uterus at least 6 months prior to dosing or naturally postmenopausal for at least one year with a Screening FSH leve≥l 40 mIU/L). - - A negative serum pregnancy test is required at Screening for females.
Exclusion Criteria:
- Regular use of medication, except contraceptive, vitamin tablets, treatment with antimicrobial agents within the 3 months preceding the study, Use of antibiotics for 4 weeks prior to the study drug application or use of concomitant systemic or topical antibiotics, Systemic treatment with immunosuppressive drugs e.g. cyclosporine, azathioprine or oral corticosteroids within 4 weeks prior to baseline visit (Visit 2) .
- Participation in a trial with another investigational drug within the 3 months preceding the study
- Present or residual gastrointestinal, renal insufficiency or hepatic disorder
- Abnormal pathology of nasal passages
- Any clinically significant allergy or drug intolerance
- Active hay fever, on-going cold/flu symptoms, including rhinitis at baseline (visit 2)
- Any medical history of renal insufficiency or hepatic disorder or other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs
- history of hypersensitivity to beta-lactams or tetracycline
- pregnant or breast-feeding women
Subjects known or suspected of not being able to comply with trial protocol (e.g. alcoholism, drug dependency, or psychological state). History of regular alcohol consumption exceeding an average weekly intake of alcohol greater than 21 units for female and 28 units for male.
One unit is equivalent to a half-pint of beer or one measure of spirits or one glass of wine.
- Subjects with known or suspected immunodeficiency.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 3 doses of amoxicillin daily for 7 days
Cohort A: 3 doses of amoxicillin daily for 7 days (n=14).
Follow up 12 months.
|
|
Active Comparator: 2 doses of minocycline daily for 5 days
Cohort B: 2 doses of minocycline daily for five days (n=14).
Follow up 12 months.
|
|
Placebo Comparator: 2 doses of placebo daily for 5 days
Cohort C: 2 doses of placebo daily for five days (n=14).
Follow up 12 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of resistant bacteria collected from body sites in subjects receiving minocycline/ amoxicillin compared to the baseline.
Time Frame: 12 Months
|
12 Months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse events (AEs) will be monitored throughout the study
Time Frame: 12 Months
|
12 Months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jorg Taubel, MD, Richmond Pharmacology Limited
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C09040
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Antibiotic Resistant Bacteria
-
Association Clinique Thérapeutique Infantile du...PfizerRecruitingAntibiotic Prescription | Complications | Risk Factors | Outcome, Fatal | Intensive Care Unit | Multi-antibiotic Resistance | Infection Due to Resistant Bacteria | Healing | Hospital DischargeFrance
-
University Hospital, GrenobleBecton, Dickinson and CompanyCompletedMultidrug-resistant Bacteria ScreeningFrance
-
Centre Hospitalier Régional Metz-ThionvilleCompletedMulti-drug Resistant BacteriaFrance
-
Stephen HarbarthEuropean CommissionUnknownIntestinal Colonization With Multidrug-resistant BacteriaIsrael, Switzerland, France, Netherlands
-
Association Pour le Recherche en Infectiologie...Pr Bruno FantinCompletedColonization | Hospitalized Patients | Multi Drug Resistant BacteriaFrance
-
Federal Research Institute of Pediatric Hematology...Not yet recruitingAntibiotic Resistant StrainRussian Federation
-
Cairo UniversityNot yet recruitingAntibiotic Resistant StrainEgypt
-
The Methodist Hospital Research InstituteM.D. Anderson Cancer Center; National Institute of Allergy and Infectious Diseases... and other collaboratorsRecruitingAntibiotic Resistant Infection | Clostridium Difficile | Antimicrobial Drug Resistance | Carbapenem-Resistant Enterobacteriaceae Infection | Vancomycin Resistant Enterococci Infection | Vancomycin-Resistant Enterococcal Infection | Carbapenem Resistant Bacterial Infection | Extended Spectrum Beta-Lactamase...United States
-
Virginia Commonwealth UniversityCompletedRelationship of Carbapenem Use to Carbapenem Resistant Gram-negative BacteriaUnited States
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingAntibiotic Resistant Strain | Transmission, Close-ContactFrance
Clinical Trials on 3 doses of amoxicillin daily for 7 days
-
University Hospital, MontpellierDirection Générale de l'Offre de SoinsNot yet recruitingChild, Only | Community-acquired PneumoniaFrance
-
Weill Medical College of Cornell UniversityCompletedTonsillectomyUnited States
-
LEO PharmaCompleted
-
Shandong UniversityZaozhuang Municipal Hospital; Zibo Maternal and Child Health Hospital; Binzhou... and other collaboratorsNot yet recruitingHelicobacter Pylori Infection
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedAtrophy | Vaginitis | Atrophic VaginitisUnited States, Canada
-
University of Geneva, SwitzerlandCompletedChronic PeriodontitisSwitzerland
-
The Catholic University of KoreaSt Vincent's Hospital; Bucheon St. Mary's HospitalUnknown
-
Xijing Hospital of Digestive DiseasesRecruitingthe Eradication Rates of Helicobacter PyloriChina
-
Dallas VA Medical CenterOtsuka Pharmaceutical Development & Commercialization, Inc.UnknownHelicobacter InfectionUnited States